Phase I Trial of RAD001C (Everolimus) in Pediatric Patients With Recurrent Refractory Solid Tumors or Brain Tumors.

Trial Profile

Phase I Trial of RAD001C (Everolimus) in Pediatric Patients With Recurrent Refractory Solid Tumors or Brain Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Brain cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Sep 2008 Status changed from recruiting to active, no longer recruiting as reported by CT.gov
    • 29 Nov 2007 The expected completion date for this trial is now 1 Oct 2008 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top